Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES
Gram-Negative Bacterial Infections
© 2015 by the American Association for the Study of Liver Diseases. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been variably noted to affect hepatitis C virus (HCV) treatment response, fibrosis progression, and hepatocellular carcinoma (HCC) incidence, with some having a more potent effect than others. We sought to determine the impact of adding statins to antiviral therapy upon sustained virological response (SVR) rates, fibrosis progression, and HCC development among HCV-infected persons using the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES), an established, longitudinal, national cohort of HCV-infected veterans. Within ERCHIVES, we identified those who received HCV treatment and a follow-up of >24 months after treatment completion. We excluded those with human immunodeficiency virus coinfection, hepatitis B surface antigen positivity, cirrhosis, and HCC at baseline. Our main outcomes were liver fibrosis progression measured by FIB-4 scores, SVR rates, and incident HCC (iHCC). Among 7,248 eligible subjects, 46% received statin therapy. Statin use was significantly associated with attaining SVR (39.2% vs. 33.3%; P<0.01), decreased cirrhosis development (17.3% vs. 25.2%; P<0.001), and decreased iHCC (1.2% vs. 2.6%; P<0.01). Statins remained significantly associated with increased odds of SVR (odds ratio=1.44; 95% confidence interval [CI]=1.29, 1.61), but lower fibrosis progression rate, lower risk of progression to cirrhosis (hazard ratio [HR]=0.56; 95% CI=-0.50, 0.63), and of incident HCC (HR=0.51; 95% CI=0.34, 0.76) after adjusting for other relevant clinical factors. Conclusions: Statin use was associated with improved virological response (VR) rates to antiviral therapy and decreased progression of liver fibrosis and incidence of HCC among a large cohort of HCV-positive Veterans. These data support the use of statins in patients with HCV.
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency